08:29 AM EDT, 09/20/2024 (MT Newswires) -- AbbVie ( ABBV ) said on Friday that the European Medicines Agency's advisory committee has recommended a marketing authorization for the company's ovarian cancer therapy, mirvetuximab soravtansine.

The therapy is being developed as a treatment for adult patients with platinum-resistant and epithelial ovarian, fallopian tube or primary peritoneal cancer who have been treated with up to three prior therapies.

The company said the agency's recommendation is based on results of a phase 3 trial, and a final European Commission decision is expected later this year.

AbbVie ( ABBV ) said mirvetuximab soravtansine received US Food and Drug Administration approval in March 2024 and that marketing authorizations for the treatment are being reviewed in various other countries.